# A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

> **NCT04183166** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Transgene** · enrollment: 80 (actual)

## Conditions studied

- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **DRUG:** TG4050

## Key facts

- **NCT ID:** NCT04183166
- **Lead sponsor:** Transgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-12
- **Primary completion:** 2027-12-30
- **Final completion:** 2031-12-30
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04183166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04183166, "A Clinical Trial Evaluating TG4050 in Head and Neck Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04183166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*